MARKET

GNMX

Aevi Genomic Med
GNMX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.3309
-
-3.1067
12,892,716.43
About GNMX
Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .
More

GNMX News

More
CERC: Improved Balance Sheet to Move the Pipeline Forward
Zacks Small Cap Research · 05/13 11:00
CERC: Data from CDG-FIRST Trial Upcoming
Zacks Small Cap Research · 03/19 13:50
Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine
American City Business Journals · 02/04 18:31
Cerecor and Aevi Genomic Medicine Complete Merger
GlobeNewswire · 02/03 21:15
Aevi Genomic Medicine, Inc. (GNMX): Hedge Fund Sentiment Unchanged
Insider Monkey · 12/22/2019 22:08
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
GlobeNewswire · 12/16/2019 12:30
CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
Zacks Small Cap Research · 12/13/2019 14:50
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aevi Genomic Medicine, Inc. to Independent Bank Group Inc. is Fair to Shareholders
ACCESSWIRE · 12/10/2019 20:20

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Aevi Genomic Med stock information, including NASDAQ:GNMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMX stock news, and many more online research tools to help you make informed decisions.